Marion Montastruc Selected Research

FEC protocol

1/2021

Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marion Montastruc Research Topics

Disease

4	Neoplasms (Cancer) 10/2017 - 04/2015
2	Breast Neoplasms (Breast Cancer) 01/2021 - 09/2018
1	Dihydropyrimidine Dehydrogenase Deficiency 01/2021
1	Drug-Related Side Effects and Adverse Reactions 09/2018
1	Parkinsonian Disorders (Parkinsonism) 09/2018
1	Ovarian Neoplasms (Ovarian Cancer) 10/2016

Drug/Important Bio-Agent (IBA)

1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Epirubicin (Ellence)FDA LinkGeneric 01/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	Tamoxifen FDA LinkGeneric 09/2018
1	Aromatase InhibitorsIBA 09/2018
1	Taxoids (Taxanes)IBA 10/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2016
1	Antineoplastic Agents (Antineoplastics)IBA 10/2016
1	Docetaxel (Taxotere)FDA Link 10/2016

Therapy/Procedure

2	Central Venous Catheters 09/2017 - 04/2015
1	FEC protocol 01/2021
1	Subcutaneous Injections 10/2017
1	Anesthesia 04/2015